Table 1 Comparison of pSS and non-pSS patients

Age (years, mean ± SD)

56.1 ± 13.0

56.3 ± 13.5

55.9 ± 12.7

0.89

Symptom duration (years, mean ± SD)

6.4 ± 6.9

7.0 ± 7.6

6.0 ± 6.3

0.48

Female, n (%)

167 (92.2)

70 (90.9)

97 (93.3)

0.56

Xerophthalmia, n (%)

156 (86.2)

70 (90.9)

86 (82.7)

0.11

Xerostomia, n (%)

166 (91.7)

73 (94.8)

93 (89.4)

0.19

Abnormal Schirmer’s test, n (%)

76 (42.0)

44 (57.1)

32 (30.8)

<0.001

Decreased salivary flow, n (%)

80 (44.2)

48 (62.3)

32 (30.8)

<0.001

Abnormal salivary gland biopsy, n (%)

75 (41.4)

62 (80.5)

13 (12.5)

<0.001

Anti-SSA or -SSB positivity, n (%)

47 (26.0)

47 (61.0)

0 (0.0)

<0.001

AECG criteria, n (%)

67 (37.0)

64 (83.1)

3 (2.9)

<0.001

Anti-SSA positivity, n (%)

47 (26.0)

47 (61.0)

0 (0.0)

<0.001

Anti-SSB positivity, n (%)

25 (13.8)

25 (32.5)

0 (0.0)

<0.001

ANA ≥1:320, n (%)

105 (58.0)

62 (80.5)

43 (41.3)

<0.001

ANA ≥1:640, n (%)

73 (40.3)

54 (70.1)

19 (18.3)

<0.001

IgM-RF positivity, n (%)

56 (30.9)

35 (45.5)

21 (20.2)

<0.001

IgA-RF positivity, n (%)

37 (20.4)

32 (41.6)

5 (4.8)

<0.001

Gammaglobulins ≥14 g/L, n (%)

44 (24.3)

36 (46.8)

8 (7.7)

<0.001

IgG ≥14 g/L, n (%)

47 (26.0)

38 (49.4)

9 (8.7)

<0.001

B-cell ratio ≥5, n (%)

59 (32.6)

41 (53.2)

18 (17.3)

<0.001

ANA ≥1:320 + IgM-RF, n (%)

39 (21.5)

32 (41.6)

7 (6.7)

<0.001

ACR criteria serologic item, n (%)

56 (30.9)

49 (63.6)

7 (6.7)

<0.001